The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
Publication of IARC Handbooks of Cancer Prevention Volume 18: Cervical Cancer Screening06/05/2022
This publication is an important update of the previous IARC Handbook on cervical cancer screening (Volume 10, published in 2005). Volume 18 provides evidence-based evaluations of the effectiveness of five methods of cervical cancer screening in reducing cervical cancer incidence and/or mortality. The Working Group also reviewed the body of evidence and provided conclusive statements on the comparative effectiveness of those screening methods that are established to reduce cervical cancer incidence and/or mortality. In addition, the Working Group provided an updated literature review on the determinants of participation in screening programmes and on emerging techniques, as well as on the different categories of women at differential risk and the surveillance strategies for such women.
View the publication.
Training for non-radiologist clinicians to perform breast ultrasound and manage lesions suspicious of cancer02/05/2022 – 06/05/2022
Within the framework of the project, Evaluation of a portable ultrasound device to triage the women positive on clinical breast examination by trained healthcare workers and medical officers, organized in Kannur, India by the Malabar Cancer Society in collaboration with BARC and IARC, staff involved in this project were trained to perform breast ultrasound on CBE positive women and learn to differentiate features of benign breast lesions from the suspicious and malignant ones.
Principal investigators meeting: SaveCervix29/04/2022 – 30/04/2022
In collaboration with the All India Institute of Medical Sciences (New Delhi, India), the Cancer Institute (WIA) Chennai (Chennai, India), and the Chittaranjan National Cancer Institute (CNCI) (Kolkata, India), the Early Detection, Prevention & Infections Branch/IARC organized today the SAVE-Cervix PI meeting in Kolkata, India to discuss about the development and evaluation of an artificial intelligence (AI) image recognition device to improve cervical pre-cancer screening and management in low- and middle-income countries. View the SAVE-Cervix research summary page.
New publication: Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study28/04/2022
New article was published in the Journal of International Journal of Cancer. The triage performance and predictive value of human gene methylation panel alone and with combination of HPV16/18 genotyping were evaluated based on a prospective cohort with 1,758 women with positive result for hrHPV on self-collected samples. The results revealed that the triage performance of the methylation panel alone or in combination with HPV16/18 had satisfactory balance between sensitivity and specificity. Moreover, the negative result of above triage conferred the substantial low 3-year risk of incident CIN 2+. View the article.
Principal investigators meeting for the HPV vaccination study to evaluate the effectiveness of one, two, and three doses of quadrivalent HPV vaccine in preventing cervical neoplasia, Delhi, India19/04/2022 – 21/04/2022
The Screening Group organized this meeting for all principal investigators, programme managers, and key collaborators from the study sites involved in this project, to discuss Data and Safety Monitoring Board (DSMB) recommendations, study progress, and recent findings.
|Banerjee D., Mittal S., Mandal R., Basu P. Screening technologies for cervical cancer: Overview. Cytojournal. 2022 Mar 29;19:23. doi: 10.25259/CMAS_03_04_2021.|
|Benider A., Bendahhou K., Sauvaget C., Mrabti H., Selmouni F., Muwonge R., Alaoui L., Lucas E., Chami Y., Abousselham L., Bennani M., Errihani H., Sankaranarayanan R., Bekkali R., Basu P. Evolution of patterns of care for women with cervical cancer in Morocco over a decade. BMC Cancer. 2022 May 2;22(1):479.|
|Zhang L., Zhao X., Hu S., Chen S., Zhao S., Dong L., Carvalho A.L., Muwonge R., Zhao F., Basu P. Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study. Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.|